The software is designed to provide image surface map, parametric map, maximum intensity projection (MIP), subtraction, registered subtraction, and 3D display, as well as visual enhancement of time/intensity changes of breast lesions, to diagnose breast disease.
Compass has received clearance from the U.S. Food and Drug Administration (FDA) and is available for global distribution, coinciding with its launch at this month's RSNA annual meeting.
Visage, Clario team up, June 8, 2010
Clario partners with Tidal Pool, March 10, 2010
Clario signs CTRM deal, March 1, 2010
Medipattern, PenRad sign B-CAD pact, November 30, 2009
Copyright © 2010 AuntMinnie.com